IN2015DN02875A - - Google Patents
Info
- Publication number
- IN2015DN02875A IN2015DN02875A IN2875DEN2015A IN2015DN02875A IN 2015DN02875 A IN2015DN02875 A IN 2015DN02875A IN 2875DEN2015 A IN2875DEN2015 A IN 2875DEN2015A IN 2015DN02875 A IN2015DN02875 A IN 2015DN02875A
- Authority
- IN
- India
- Prior art keywords
- enzalutamide
- disclosure provides
- hyperproliferative disorders
- provides formulations
- treating hyperproliferative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261699351P | 2012-09-11 | 2012-09-11 | |
| PCT/US2013/059223 WO2014043208A1 (en) | 2012-09-11 | 2013-09-11 | Formulations of enzalutamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN02875A true IN2015DN02875A (da) | 2015-09-11 |
Family
ID=49231627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2875DEN2015 IN2015DN02875A (da) | 2012-09-11 | 2013-09-11 |
Country Status (28)
| Country | Link |
|---|---|
| US (9) | US20140179749A1 (da) |
| EP (5) | EP3971167A1 (da) |
| JP (5) | JP6404217B2 (da) |
| KR (1) | KR102225416B1 (da) |
| CN (2) | CN109897004A (da) |
| AU (2) | AU2013315619B2 (da) |
| BR (1) | BR112015005432B1 (da) |
| CA (1) | CA2884795C (da) |
| CY (1) | CY1124729T1 (da) |
| DK (1) | DK3725778T3 (da) |
| EA (2) | EA033374B9 (da) |
| ES (1) | ES2892029T3 (da) |
| HK (1) | HK1212701A1 (da) |
| HR (1) | HRP20211423T1 (da) |
| HU (1) | HUE057701T2 (da) |
| IL (1) | IL237604B (da) |
| IN (1) | IN2015DN02875A (da) |
| LT (1) | LT3725778T (da) |
| MX (3) | MX363974B (da) |
| PH (1) | PH12015500525A1 (da) |
| PL (1) | PL3725778T3 (da) |
| PT (1) | PT3725778T (da) |
| RS (1) | RS62676B1 (da) |
| SI (1) | SI3725778T1 (da) |
| TW (1) | TWI673051B (da) |
| UA (1) | UA117353C2 (da) |
| WO (1) | WO2014043208A1 (da) |
| ZA (1) | ZA201501847B (da) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109897004A (zh) | 2012-09-11 | 2019-06-18 | 麦迪威森前列腺医疗有限责任公司 | 恩杂鲁胺制剂 |
| ES2836424T3 (es) | 2012-09-26 | 2021-06-25 | Aragon Pharmaceuticals Inc | Antiandrógenos para tratar el cáncer de próstata no metastásico y resistente a la castración |
| CA2908957C (en) | 2013-04-17 | 2021-05-18 | Signal Pharmaceuticals, Llc | Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer |
| KR20200015830A (ko) * | 2014-02-05 | 2020-02-12 | 레크 파마슈티칼스 디.디. | 안드로겐 수용체 길항제의 고체 제약 조성물 |
| CN104356068A (zh) * | 2014-10-30 | 2015-02-18 | 杭州新博思生物医药有限公司 | 恩杂鲁胺新晶型及其制备方法 |
| ES2839128T3 (es) * | 2014-12-05 | 2021-07-05 | Aragon Pharmaceuticals Inc | Composiciones anticancerosas |
| MA41107A (fr) * | 2014-12-05 | 2017-10-10 | Aragon Pharmaceuticals Inc | Compositions anti-cancéreuses |
| US10285948B2 (en) | 2014-12-05 | 2019-05-14 | Janssen Pharmaceutica Nv | Anticancer compositions |
| CN104546714A (zh) * | 2015-02-11 | 2015-04-29 | 江苏慧博生物科技有限公司 | 一种恩杂鲁胺胶束制剂及其制备方法 |
| CA2976360A1 (en) * | 2015-02-11 | 2016-08-18 | Aptevo Research And Development Llc | Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins |
| CN104857517B (zh) * | 2015-05-14 | 2018-04-27 | 南京海纳医药科技股份有限公司 | 一种恩杂鲁胺软胶囊及其制备方法 |
| CN105030685B (zh) * | 2015-07-21 | 2018-02-27 | 福格森（武汉）生物科技股份有限公司 | 一种恩杂鲁胺固体分散体口服制剂 |
| WO2017027665A1 (en) | 2015-08-12 | 2017-02-16 | Medivation Prostate Therapeutics, Inc. | Treatment of cancer using a combination of enzalutamide and a cyp3a4 inducer |
| WO2017035263A1 (en) * | 2015-08-24 | 2017-03-02 | Biocryst Pharmaceuticals, Inc. | Compositions comprising a plasma kallikrein inhibitor |
| EP3352760A4 (en) | 2015-09-21 | 2019-03-06 | Aptevo Research and Development LLC | CD3 BINDING POLYPEPTIDES |
| CN107126419B (zh) * | 2016-02-26 | 2020-06-19 | 石药集团中诺药业（石家庄）有限公司 | 一种奥贝胆酸片剂及其制备方法 |
| US11478453B2 (en) | 2016-07-21 | 2022-10-25 | Hadasit Medical Research Services And Development Ltd. | Treatment for glioblastoma |
| EP3500310A1 (en) | 2016-08-20 | 2019-06-26 | FTF Pharma Private Limited | Pharmaceutical composition comprising an androgen receptor inhibitor |
| EP3609464B1 (en) * | 2017-04-13 | 2021-05-26 | Jean Paul Remon | Xanthohumol-based compositions |
| KR20190137920A (ko) | 2017-04-28 | 2019-12-11 | 아스텔라스세이야쿠 가부시키가이샤 | 엔잘루타미드를 함유하는 경구 투여용 의약 조성물 |
| BR112019027402A2 (pt) | 2017-06-22 | 2020-07-07 | Celgene Corporation | tratamento de carcinoma hepatocelular caracterizado por infecção pelo vírus da hepatite b |
| WO2019016747A1 (en) * | 2017-07-20 | 2019-01-24 | Dr. Reddy's Laboratories Limited | AMORPHOUS SOLID DISPERSIONS OF APALUTAMIDE AND PROCESS FOR THEIR PREPARATION |
| RU2020109948A (ru) * | 2017-08-08 | 2021-09-10 | Др. Редди'З Лабораториз Лимитед | Экструдированные композиции энзалутамида |
| EP3697398A1 (en) | 2017-10-16 | 2020-08-26 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer |
| WO2019155416A2 (en) * | 2018-02-09 | 2019-08-15 | Kashiv Pharma Llc | A stable pharmaceutical composition of poorly soluble nonsteroidal antiandrogens |
| JP7244536B2 (ja) * | 2018-04-06 | 2023-03-22 | キャプシュゲル・ベルジウム・エヌ・ヴィ | メタクリル酸メチル－メタクリル酸コポリマーからなる低アスペクト比の粒子のための噴霧乾燥方法 |
| CZ2018234A3 (cs) | 2018-05-21 | 2019-12-04 | Zentiva Ks | Zvýšení rozpustnosti a biodostupnosti enzalutamidu |
| EA202191372A1 (ru) * | 2018-12-14 | 2021-09-16 | Фуджифилм Корпорэйшн | Таблетка и способ получения таблетки |
| CN109432016B (zh) * | 2018-12-26 | 2021-03-02 | 广州中医药大学(广州中医药研究院) | 一种恩杂鲁胺的三元固体制剂及其制备方法 |
| WO2020144647A1 (en) | 2019-01-10 | 2020-07-16 | Aragon Pharmaceuticals, Inc. | Pharmaceutical composition comprising apalutamide dispersed in apple sauce |
| EP3918607A1 (en) | 2019-01-30 | 2021-12-08 | Janssen Pharmaceutica NV | Methods of treating prostate cancer based on molecular subtypes |
| EP3917519A1 (en) | 2019-01-30 | 2021-12-08 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer |
| WO2020229702A1 (en) | 2019-05-16 | 2020-11-19 | Leon-Nanodrugs Gmbh | Method for producing nanoparticles |
| JP2022533463A (ja) | 2019-05-23 | 2022-07-22 | ヘルム・アクチエンゲゼルシャフト | エンザルタミドを含むナノ粒子 |
| WO2020239478A1 (en) | 2019-05-28 | 2020-12-03 | Pharma Mar, S.A. | Trabectedin for treating sarcomas based on genomic markers |
| US20220242829A1 (en) | 2019-06-27 | 2022-08-04 | Synthon B.V. | Process for preparation of enzalutamide |
| CN114727949A (zh) * | 2019-09-18 | 2022-07-08 | 百时美施贵宝公司 | Tyk2抑制剂的剂型 |
| US20230147869A1 (en) * | 2019-09-23 | 2023-05-11 | Bionomics Limited | Therapeutic formulations and uses thereof |
| US20220347102A1 (en) | 2019-10-03 | 2022-11-03 | Synthon B.V. | Pharmaceutical composition comprising enzalutamide |
| JP2023500935A (ja) | 2019-11-04 | 2023-01-11 | アラゴン ファーマシューティカルズ，インコーポレイテッド | 重度の肝障害を有する対象における非転移性去勢抵抗性前立腺癌の治療のためのアンドロゲン受容体阻害剤 |
| AR118925A1 (es) * | 2020-05-13 | 2021-11-10 | Novocap S A | Solución líquida concentrada de antiandrógenos no esteroideos y procedimiento para preparar la solución |
| WO2021240206A1 (en) | 2020-05-24 | 2021-12-02 | Lotus International Pte. Ltd. | Enzalutamide formulation |
| WO2021245285A1 (en) | 2020-06-05 | 2021-12-09 | Janssen Pharmaceutica Nv | Methods of treating prostate cancer based on molecular subtypes |
| CN114053243A (zh) * | 2020-08-05 | 2022-02-18 | 齐鲁制药有限公司 | 一种恩扎卢胺软胶囊及其制备方法 |
| WO2022049523A1 (en) | 2020-09-04 | 2022-03-10 | Aragon Pharmaceuticals, Inc. | Methods for treating prostate cancer |
| WO2022195407A1 (en) | 2021-03-19 | 2022-09-22 | Aragon Pharmaceuticals, Inc. | Methods for treating prostate cancer |
| CN115721612A (zh) * | 2021-08-26 | 2023-03-03 | 上海宣泰医药科技股份有限公司 | 一种恩扎卢胺固体制剂颗粒及其制备方法 |
| WO2023138366A1 (zh) * | 2022-01-19 | 2023-07-27 | 四川科伦药物研究院有限公司 | 固体分散体及其制备方法和包含其的药物组合物 |
| CN114224832A (zh) * | 2022-02-11 | 2022-03-25 | 明度智云(浙江)科技有限公司 | 一种恩杂鲁胺注射剂及其制备方法和应用 |
| WO2023152611A1 (en) | 2022-02-11 | 2023-08-17 | Aragon Pharmaceuticals, Inc. | Apalutamide and relugolix for the treatment of prostate cancer |
| WO2023209555A1 (en) | 2022-04-26 | 2023-11-02 | Aragon Pharmaceuticals, Inc. | Approved drug products and methods for treating prostate cancer |
| WO2023244617A1 (en) * | 2022-06-13 | 2023-12-21 | Virginia Polytechnic Institute And State University | Amphiphilic cellulose derivatives, methods of making, and uses thereof |
| WO2023244684A1 (en) * | 2022-06-17 | 2023-12-21 | Tranquis Therapeutics, Inc. | Formulations of 2-arylbenzimidazole compounds |
| CN115887395A (zh) * | 2022-11-18 | 2023-04-04 | 上海药坦药物研究开发有限公司 | 恩杂鲁胺固体分散体制剂及其制备方法和应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5656651A (en) * | 1995-06-16 | 1997-08-12 | Biophysica Inc. | Androgenic directed compositions |
| TW486370B (en) * | 1996-12-25 | 2002-05-11 | Yamanouchi Pharma Co Ltd | Rapidly disintegrable pharmaceutical composition |
| EP1741424B1 (en) | 1997-08-11 | 2018-10-03 | Pfizer Products Inc. | Solid pharmaceutical dispersions with enhanced bioavailabilty |
| DK0901786T3 (da) | 1997-08-11 | 2007-10-08 | Pfizer Prod Inc | Faste farmaceutiske dispersioner med foröget biotilgængelighed |
| IN191496B (da) | 1999-07-30 | 2003-12-06 | Ranbaxy Lab Ltd | |
| US20010053778A1 (en) | 2000-03-16 | 2001-12-20 | Hoover Dennis J. | Pharmaceutical compositions of glycogen phosphorylase inhibitors |
| CA2439366A1 (en) | 2001-02-27 | 2002-09-06 | Julie Cahill | Pharmaceutical formulation comprising bicalutamide |
| SE0103424D0 (sv) | 2001-10-15 | 2001-10-15 | Astrazeneca Ab | Pharmaceutical formulation |
| GB2383042A (en) | 2001-10-18 | 2003-06-18 | Cipla Ltd | Amorphous alendronate sodium |
| SE0103839D0 (sv) | 2001-11-16 | 2001-11-16 | Astrazeneca Ab | Pharmaceutical formulation & product |
| JP2005523260A (ja) * | 2002-02-01 | 2005-08-04 | ファイザー・プロダクツ・インク | 圧力ノズルを用いた均質噴霧乾燥固体非晶質薬剤分散体の製造方法 |
| US20050165185A1 (en) * | 2002-04-18 | 2005-07-28 | Spivey Alan C. | Preparation of a conjugated molecule and materials for use therein |
| JP4249950B2 (ja) | 2002-06-28 | 2009-04-08 | 富士フイルム株式会社 | 紙管切断装置及び紙管切断方法 |
| WO2004074350A2 (en) * | 2003-02-21 | 2004-09-02 | Hetero Drugs Limited | Bicalutamide polymorphs |
| EP1730516A1 (en) | 2004-03-30 | 2006-12-13 | Pfizer Products Incorporated | Method and device for evaluation of pharmaceutical compositions |
| US7709517B2 (en) * | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
| ES2535179T3 (es) | 2005-05-13 | 2015-05-06 | The Regents Of The University Of California | Compuesto de diarilhidantoína como antagonistas de los receptores de andrógenos para el tratamiento de cáncer |
| JP2008540629A (ja) * | 2005-05-19 | 2008-11-20 | ファイザー・インク | 非晶形のｖｅｇｆ−ｒ阻害剤を含む医薬組成物 |
| WO2007014393A2 (en) | 2005-07-28 | 2007-02-01 | Isp Investments Inc. | Amorphous efavirenz and the production thereof |
| DK2368550T3 (da) | 2006-03-27 | 2013-09-30 | Univ California | Androgenreceptormodulator til behandlingen af prostatakræft og androgenreceptor-associerede sygdomme |
| WO2008080037A2 (en) | 2006-12-21 | 2008-07-03 | Isp Investments Inc. | Carotenoids of enhanced bioavailability |
| EP2134327A1 (en) | 2007-03-13 | 2009-12-23 | Sandoz AG | Pharmaceutical compositions of poorly soluble drugs |
| KR101569227B1 (ko) | 2008-03-11 | 2015-11-13 | 아스카 세이야쿠 가부시키가이샤 | 고체 분산체와 그 의약 조성물, 그리고 그들의 제조 방법 |
| CR20170089A (es) | 2009-04-03 | 2017-07-17 | Plexxikon Inc | Composiciones del acido propano-1--sulfonico {3-[5-(4-cloro-fenil)-1h-pirrolo [2,3-b] piridina-3-carbonil] -2,4-difluoro-fenil}-amida y el uso de las mismas |
| US20100297194A1 (en) * | 2009-04-30 | 2010-11-25 | Nathaniel Catron | Formulation for oral administration of apoptosis promoter |
| BR112012021406B1 (pt) * | 2010-02-24 | 2021-08-10 | Medivation Prostate Therapeutics Llc | Processos para a síntese dos compostos de diariltioidantoína e diarilidantoína |
| UA104517C2 (uk) * | 2010-03-10 | 2014-02-10 | Ебботт Леборетріз | Тверда композиція, що є корисною в лікуванні інфекції вірусу гепатиту с, та способи її одержання |
| PL3533792T3 (pl) | 2012-06-07 | 2021-11-29 | Aragon Pharmaceuticals, Inc. | Postacie krystaliczne modulatora receptora androgenowego |
| TWI595715B (zh) * | 2012-08-10 | 2017-08-11 | 奇沙公司 | 用於極高頻通訊之介電耦接系統 |
| US9713594B2 (en) | 2012-09-11 | 2017-07-25 | Bend Research, Inc. | Methods for making pharmaceutical solid dosage forms of spray-dried dispersions |
| KR20150053963A (ko) | 2012-09-11 | 2015-05-19 | 닥터 레디스 레보러터리즈 리미티드 | 엔잘루타마이드 다형태 및 그의 제조 |
| CN109897004A (zh) | 2012-09-11 | 2019-06-18 | 麦迪威森前列腺医疗有限责任公司 | 恩杂鲁胺制剂 |
| WO2014167428A2 (en) | 2013-04-10 | 2014-10-16 | Shilpa Medicare Limited | Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide |
| KR20190137920A (ko) | 2017-04-28 | 2019-12-11 | 아스텔라스세이야쿠 가부시키가이샤 | 엔잘루타미드를 함유하는 경구 투여용 의약 조성물 |
| US20190208236A1 (en) | 2018-01-02 | 2019-07-04 | Source Digital, Inc. | Coordinates as ancillary data |
| US20220347102A1 (en) | 2019-10-03 | 2022-11-03 | Synthon B.V. | Pharmaceutical composition comprising enzalutamide |
-
2013
- 2013-09-11 CN CN201811517651.2A patent/CN109897004A/zh active Pending
- 2013-09-11 LT LTEP20177837.0T patent/LT3725778T/lt unknown
- 2013-09-11 EP EP21190086.5A patent/EP3971167A1/en not_active Withdrawn
- 2013-09-11 AU AU2013315619A patent/AU2013315619B2/en active Active
- 2013-09-11 JP JP2015531335A patent/JP6404217B2/ja active Active
- 2013-09-11 US US14/023,878 patent/US20140179749A1/en not_active Abandoned
- 2013-09-11 EP EP20177837.0A patent/EP3725778B1/en active Active
- 2013-09-11 BR BR112015005432-3A patent/BR112015005432B1/pt active IP Right Grant
- 2013-09-11 PT PT201778370T patent/PT3725778T/pt unknown
- 2013-09-11 EP EP22197255.7A patent/EP4169908A1/en not_active Withdrawn
- 2013-09-11 ES ES20177837T patent/ES2892029T3/es active Active
- 2013-09-11 MX MX2015003140A patent/MX363974B/es active IP Right Grant
- 2013-09-11 EA EA201500314A patent/EA033374B9/ru not_active IP Right Cessation
- 2013-09-11 WO PCT/US2013/059223 patent/WO2014043208A1/en active Application Filing
- 2013-09-11 KR KR1020157009040A patent/KR102225416B1/ko active IP Right Grant
- 2013-09-11 RS RS20211117A patent/RS62676B1/sr unknown
- 2013-09-11 PL PL20177837T patent/PL3725778T3/pl unknown
- 2013-09-11 TW TW102132800A patent/TWI673051B/zh active
- 2013-09-11 EA EA201991484A patent/EA201991484A1/ru unknown
- 2013-09-11 SI SI201331927T patent/SI3725778T1/sl unknown
- 2013-09-11 EP EP13766437.1A patent/EP2895463A1/en not_active Withdrawn
- 2013-09-11 HU HUE20177837A patent/HUE057701T2/hu unknown
- 2013-09-11 US US14/023,637 patent/US20140100256A1/en not_active Abandoned
- 2013-09-11 DK DK20177837.0T patent/DK3725778T3/da active
- 2013-09-11 IN IN2875DEN2015 patent/IN2015DN02875A/en unknown
- 2013-09-11 CN CN201380055471.6A patent/CN105358535B/zh active Active
- 2013-09-11 CA CA2884795A patent/CA2884795C/en active Active
- 2013-09-11 HR HRP20211423TT patent/HRP20211423T1/hr unknown
- 2013-09-11 UA UAA201503119A patent/UA117353C2/uk unknown
- 2013-09-11 EP EP23205739.8A patent/EP4324527A3/en active Pending
-
2014
- 2014-09-10 US US14/481,986 patent/US20140378517A1/en not_active Abandoned
-
2015
- 2015-03-08 IL IL237604A patent/IL237604B/en unknown
- 2015-03-11 MX MX2021000007A patent/MX2021000007A/es unknown
- 2015-03-11 MX MX2019003984A patent/MX2019003984A/es unknown
- 2015-03-11 PH PH12015500525A patent/PH12015500525A1/en unknown
- 2015-03-18 ZA ZA2015/01847A patent/ZA201501847B/en unknown
-
2016
- 2016-01-22 HK HK16100714.7A patent/HK1212701A1/zh unknown
- 2016-02-08 US US15/018,078 patent/US20170027910A1/en not_active Abandoned
- 2016-09-09 JP JP2016176557A patent/JP2016204392A/ja active Pending
- 2016-09-16 US US15/267,352 patent/US20170224624A1/en not_active Abandoned
-
2018
- 2018-01-15 AU AU2018200316A patent/AU2018200316A1/en not_active Abandoned
- 2018-01-26 JP JP2018011759A patent/JP2018087206A/ja active Pending
- 2018-07-24 US US16/044,255 patent/US20190209476A1/en not_active Abandoned
-
2019
- 2019-04-01 US US16/371,618 patent/US20200060976A1/en not_active Abandoned
- 2019-08-08 JP JP2019146714A patent/JP6932746B2/ja active Active
-
2021
- 2021-08-17 JP JP2021132868A patent/JP2021178871A/ja active Pending
- 2021-09-14 CY CY20211100809T patent/CY1124729T1/el unknown
-
2022
- 2022-11-11 US US17/985,220 patent/US20230122911A1/en active Pending
- 2022-11-11 US US17/985,235 patent/US11839689B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015500525A1 (en) | Formulations of enzalutamide | |
| IL239355A0 (en) | Compositions of gamma-hydroxybutyrate and their use in the treatment of disorders | |
| HK1217289A1 (zh) | 使用細菌治療癌症的組合物和方法 | |
| PH12014502132A1 (en) | Anti-lgr5 antibodies and immunoconjugates | |
| IN2015DN00127A (da) | ||
| MY168032A (en) | Warm-Cool Beauty Treatment Device | |
| IN2014DN11201A (da) | ||
| IL238177A0 (en) | Methods and preparations for the treatment of cancer | |
| PH12014501605A1 (en) | Anti-lrp5 antibodies and methods of use | |
| EP2897689A4 (en) | COMPOSITIONS AND METHODS OF TREATING ALOPEZIA | |
| IL239374A0 (en) | Preparations and methods for treating brain tumors | |
| MX2016008150A (es) | Formulaciones de berberina y usos de las mismas. | |
| ZA201408055B (en) | Compositions and methods for the treatment of local pain | |
| GEP201706764B (en) | Quinazolin-thf-amines as pde1 inhibitors | |
| ZA201408060B (en) | Compositions and methods for the treatment of neurological disorders | |
| EA201590615A1 (ru) | Стимулирующие лактацию композиции на основе фосфатидилсерина | |
| EP2800568A4 (en) | COMPOSITIONS, USE METHOD AND TREATMENT METHOD THEREFOR | |
| GEP20186920B (en) | Halogenated quinazolinthf-amines as pde1 inhibitors | |
| ZA201408061B (en) | Compositions and methods for the treatment of neurological disorders | |
| EP2825184A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PAIN | |
| MY168958A (en) | Intermediates and processes for preparing compounds | |
| AU2013902004A0 (en) | Compositions for Therapy and Methods of Treatment | |
| UA80618U (en) | Use of n-steroylethanolamine as radiomodifier | |
| AU2012902296A0 (en) | Compositions for Therapy and Methods of Treatment |